{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:41:11Z","timestamp":1786995671066,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,22]],"date-time":"2019-12-22T00:00:00Z","timestamp":1576972800000},"content-version":"vor","delay-in-days":296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2014\/06959-0"],"award-info":[{"award-number":["2014\/06959-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2014\/24400-0"],"award-info":[{"award-number":["2014\/24400-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2017\/07010-2"],"award-info":[{"award-number":["2017\/07010-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2017\/04926-6"],"award-info":[{"award-number":["2017\/04926-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"crossref","award":["385282\/2011-7"],"award-info":[{"award-number":["385282\/2011-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"crossref","award":["304339\/2017-2"],"award-info":[{"award-number":["304339\/2017-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.phrs.2018.12.006","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T12:35:04Z","timestamp":1544531704000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["ER stress promotes antitumor effects in BRAFi\/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC)"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-9292","authenticated-orcid":false,"given":"D\u00e9bora Kristina","family":"Alves-Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rica Aparecida de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Fai\u00e3o-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Alicea-Rebecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashani T.","family":"Weeraratna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiran S.M.","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Berlanga de Moraes","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvya Stuchi","family":"Maria-Engler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.phrs.2018.12.006_bib0005","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.191999.112","article-title":"Melanoma: from mutation to medicine","volume":"26","author":"Tsao","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.phrs.2018.12.006_bib0010","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"New Eng. J. Med"},{"issue":"2","key":"10.1016\/j.phrs.2018.12.006_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.phrs.2018.12.006_bib0020","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bcp.2013.01.018","article-title":"Fibroblast-mediated drug resistance in cancer","volume":"85","author":"Paraiso","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2018.12.006_bib0025","unstructured":"FDA, U.S. Food and Drug Administration. Approved Drugs \u2013 Trametinib\/Dabrafenib - http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm476837.htm.Acesso em. 12.12.2015."},{"issue":"33","key":"10.1016\/j.phrs.2018.12.006_bib0030","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2014.57.3535","article-title":"Combined BRAF (dabrafenib and MEK inhibition (trametinib) in patients with BRAF V600- mutant melanoma experiencing progression with single-agent BRAF inhibitor","volume":"32","author":"Johnson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2018.12.006_bib0035","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s10495-008-0221-x","article-title":"Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin","volume":"13","author":"Bakhshi","year":"2008","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.phrs.2018.12.006_bib0040","doi-asserted-by":"crossref","first-page":"e4161","DOI":"10.1371\/journal.pone.0004161","article-title":"Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors","volume":"4","author":"Drexler","year":"2009","journal-title":"Plos One"},{"issue":"24","key":"10.1016\/j.phrs.2018.12.006_bib0045","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.1158\/0008-5472.CAN-05-2370","article-title":"Bortezomib sensitizes pancreatic cancer cells to endoplasmatic reticulum stress-mediated apoptosis","volume":"65","author":"Nawrocki","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2018.12.006_bib0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10637-012-9871-1","article-title":"A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production","volume":"31","author":"Maria","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.phrs.2018.12.006_bib0055","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cell.2010.02.034","article-title":"Endoplasmic reticulum stress and the inflammatory basis of metabolic disease","volume":"140","author":"Hotamisligil","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.12.006_bib0060","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1755-148X.2008.00467.x","article-title":"Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma","volume":"21","author":"Hersey","year":"2008","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.phrs.2018.12.006_bib0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1471-4892(01)00063-7","article-title":"Natural products in anticancer therapy","volume":"1","author":"Da Rocha","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.12.006_bib0070","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s12094-007-0138-9","article-title":"Natural products as leads to anticancer drugs","volume":"9","author":"Gordaliza","year":"2007","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.phrs.2018.12.006_bib0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tiv.2008.11.004","article-title":"Apoptosis induction by 4-nerolidylcatechol in melanoma cell lines","volume":"23","author":"Brohem","year":"2009","journal-title":"Toxicol. In Vitro"},{"issue":"3","key":"10.1016\/j.phrs.2018.12.006_bib0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1755-148X.2012.00992.x","article-title":"Proteasome inhibition and ROS generation by 4-nerolidylcatecol induces melanoma cell death","volume":"25","author":"Brohem","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"issue":"2","key":"10.1016\/j.phrs.2018.12.006_bib0085","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s13277-013-0653-y","article-title":"The curcumin analog DM-1 induces cell death in melanoma","volume":"34","author":"Fai\u00e3o-Flores","year":"2013","journal-title":"Tumor Biol."},{"issue":"Pt B","key":"10.1016\/j.phrs.2018.12.006_bib0090","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.phrs.2017.08.018","article-title":"Toxicogenomic and bioinformatics platforms to identify key molecular mechanisms of a curcumin-analogue DM-1 toxicity in melanoma cells","volume":"125","author":"Oliveira","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.12.006_bib0095","doi-asserted-by":"crossref","first-page":"33078","DOI":"10.1074\/jbc.M607904200","article-title":"The marine product cephalostatin 1 activates an endoplasmic reticulum stress-specific and apoptosome-independent apoptotic signaling pathway","volume":"281","author":"L\u00f3pez-Ant\u00f3n","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.12.006_bib0100","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1158\/1535-7163.MCT-09-0700","article-title":"A novel inhibitor of the sarcoplasmic\/endoplasmic reticulum Ca2+ atpase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis","volume":"9","author":"Law","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2018.12.006_bib0105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2005-05-1923","article-title":"Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL","volume":"107","author":"Carew","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2018.12.006_bib0110","first-page":"114","article-title":"Antioxidant activity of ethanolic extracts of Photomorphe umbellata L","volume":"48","author":"Barros","year":"1996","journal-title":"Miq. Ci\u00eancia e Cultura"},{"key":"10.1016\/j.phrs.2018.12.006_bib0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1562\/2005-06-29-RA-596","article-title":"In vitro and in vivo inhibition of skin matrix metalloproteinases by pothomorphe umbellata root extract","volume":"82","author":"Ropke","year":"2006","journal-title":"Photochem. Photobiol."},{"issue":"3","key":"10.1016\/j.phrs.2018.12.006_bib0120","first-page":"1","article-title":"4-nerolidylcathecol induces autophagy in human glioblastoma cells","volume":"53","author":"Massaro","year":"2017","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2018.12.006_bib0125","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejphar.2015.08.024","article-title":"4-nerolidylcathecol analogues as promising antic\u00e2ncer agents","volume":"765","author":"Cortez","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2018.12.006_bib0130","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/13880209.2017.1311351","article-title":"4-nerolidylcathechol: apoptosis by mitochondrial mechanisms with reduction in cyclin D1 at G0\/G1 stage of the chronic myelogenous K562 cell line","volume":"55","author":"Benfica","year":"2017","journal-title":"Pharm Biol."},{"key":"10.1016\/j.phrs.2018.12.006_bib0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-2006-957767","article-title":"4-nerolidylcatechol from pothomorphe spp. scavenges peroxyl radicals and inhibits Fe(ll)-dependent DNA damage","volume":"63","author":"Desmarchelier","year":"1997","journal-title":"Planta Med."},{"key":"10.1016\/j.phrs.2018.12.006_bib0140","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/onc.2016.348","article-title":"Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells","volume":"36","author":"Fai\u00e3o-Flores","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2018.12.006_bib0145","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.phrs.2016.07.017","article-title":"Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation","volume":"111","author":"Sandri","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"7326","key":"10.1016\/j.phrs.2018.12.006_bib0150","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.12.006_bib0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay fro cell growth and survival","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods N."},{"issue":"5","key":"10.1016\/j.phrs.2018.12.006_bib0160","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-06-0084","article-title":"Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases","volume":"5","author":"Smalley","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2018.12.006_bib0165","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2018.12.006_bib0170","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature17392","article-title":"sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance","volume":"532","author":"Kaur","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.12.006_bib0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2008-1074908","article-title":"4- Nerolidylcathecol from pothomorphe umbellata","volume":"39","author":"Kijjoa","year":"1980","journal-title":"Planta Med."},{"key":"10.1016\/j.phrs.2018.12.006_bib0180","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/jid.2011.147","article-title":"Mechanisms of resistance to RAF inhibitors in melanoma","volume":"131","author":"Aplin","year":"2011","journal-title":"Soc. Invest. Dermatol."},{"key":"10.1016\/j.phrs.2018.12.006_bib0185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/sj.bjc.6604891","article-title":"Integrating BRAF\/MEK inhibitors into combination therapy for melanoma","volume":"100","author":"Smalley","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2018.12.006_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/354191","article-title":"RAS\/RAF\/MEK\/ERK and PI3K\/PTEN\/AKT signaling in malignant melanoma progression and therapy","author":"Yagima","year":"2012","journal-title":"Dermat. Res. Pract."},{"key":"10.1016\/j.phrs.2018.12.006_bib0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc3218","article-title":"From genes to drugs: target strategies fro melanoma","volume":"12","author":"Flaherty","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2018.12.006_bib0200","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS mutant melanoma: biological behavior and future strategies for therapeutic management","volume":"32","author":"Fedorenko","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2018.12.006_bib0205","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrclinonc.2013.83","article-title":"Paradoxical oncogenesis \u2013 the long-term effects of BRAF inhibition in melanoma","volume":"10","author":"Gibney","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.12.006_bib0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","article-title":"Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next?","volume":"62","author":"Welsh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2018.12.006_bib0215","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","article-title":"PAK signaling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","volume":"550","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.12.006_bib0220","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic and efficcy data for the oral MEK inhibitor Trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2018.12.006_bib0225","first-page":"376","article-title":"Dermatologic toxicities to targeted cancer therapy: shared clinical and histological adverse skin reactions","volume":"53","author":"Curry","year":"2014","journal-title":"Pharmacol. Therapeutics"},{"issue":"26","key":"10.1016\/j.phrs.2018.12.006_bib0230","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.phrs.2018.12.006_bib0235","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2014.09.002","article-title":"Comparative profile of cutaneous adverse events: BRAF\/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma","volume":"71","author":"Sanlorenzo","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2018.12.006_bib0240","doi-asserted-by":"crossref","first-page":"462","DOI":"10.15252\/embj.201592081","article-title":"Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP\/TAZ activation","volume":"35","author":"Kim","year":"2016","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.phrs.2018.12.006_bib0245","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2018.12.006_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms6712","article-title":"Low MITF:AXL ratio predicts early resistance to multiple target drugs in melanoma","volume":"5","author":"Muller","year":"2014","journal-title":"Nat Commun."},{"issue":"7","key":"10.1016\/j.phrs.2018.12.006_bib0255","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.phrs.2018.12.006_bib0260","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4161\/cbt.5.7.2971","article-title":"Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress","volume":"5","author":"Fribley","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.phrs.2018.12.006_bib0265","first-page":"880","volume":"Vol. 7","author":"Szegezdi","year":"2006"},{"key":"10.1016\/j.phrs.2018.12.006_bib0270","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1097-2765(00)80283-X","article-title":"ASK1 is essential for JNK\/SAPK activation by TRAF2","volume":"2","author":"Nishitoh","year":"1998","journal-title":"Mol Cell."},{"issue":"6892","key":"10.1016\/j.phrs.2018.12.006_bib0275","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2018.12.006_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.211","article-title":"Role of endoplasmic reticulum stress in drug-induced toxicity","volume":"4","author":"Foufelle","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.phrs.2018.12.006_bib0285","unstructured":"D.K. Alves-Fernandes, E.A. Oliveira, A.A. Hastreiter, et al. Cytotoxic effects induced by 4-nerolidylcathecol (4-NC) in NRAS mutant melanoma xenograft models. Manuscript in preparation."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818319716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818319716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:56:20Z","timestamp":1760910980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818319716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":57,"alternative-id":["S1043661818319716"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.12.006","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ER stress promotes antitumor effects in BRAFi\/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC)","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}